Papers
1
Total Citations
25
H-Index
1
About
Dr. Zafar Malik is a leading oncologist whose research has fundamentally shaped the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC). His work is centered on improving therapeutic outcomes for patients with advanced genitourinary malignancies, particularly through the clinical application of next-generation chemotherapies. Dr. Malik’s most significant contribution is his landmark analysis of the compassionate use and early access programmes for cabazitaxel. This pivotal study, which has garnered 25 citations, provided crucial real-world evidence on the efficacy and safety of cabazitaxel in a heavily pre-treated patient population, validating its role as a vital third-line option beyond docetaxel. By pooling data from international cohorts, his research offered robust, pragmatic insights that directly informed clinical guidelines and expanded treatment access for patients with limited options. Affiliated with The Clatterbridge Cancer Centre NHS Foundation Trust, Dr. Malik’s work bridges the gap between clinical trials and everyday practice, ensuring that complex trial data translates into tangible survival benefits. His rigorous, patient-focused approach continues to drive progress in the fight against resistant prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1